CCL2 and hepatocellular carcinoma: A previous report has revealed that as FPR2 agonist, LL-37 triggers FPR2 and subsequent ROS/MAPK/NF-kB signaling, upregulates M-CSF/MCP-1 expression, leads to M2b- or M2d-like polarization, and exacerbates HCC invasion in vitro and in vivo [40].